Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
Y90 ibritumomab, rx (HCPCS A9543RR) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved June 28, 2026 , from http://ppman.hank.ai/transparency/procedure/A9543RR/by-state?code_type=HCPCS
“Y90 ibritumomab, rx (HCPCS A9543RR) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/A9543RR/by-state?code_type=HCPCS. Accessed
June 28, 2026 .
“Y90 ibritumomab, rx (HCPCS A9543RR) by State,” HANK Price Transparency ,
accessed June 28, 2026 ,
http://ppman.hank.ai/transparency/procedure/A9543RR/by-state?code_type=HCPCS.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
HCPCS · across United States
A9543RR — Y90 Ibritumomab, Rx
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$130,953
National median
$130,953 – $130,953
IQR (p25 – p75)
1
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for A9543RR (HCPCS), with interquartile range
State Median p25 p75
WI $130,953 $130,953 $130,953